

Microvascular Complications of Diabetes – Pathogenesis, Diagnosis, and Treatment

Special Edition of *The Review of Diabetic Studies*, Vol. 12, No. 1-2, 2015

Table of Contents

Chapter I. Diabetic Peripheral Neuropathy.....	11
I.1 Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy by Mark A. Yorek.....	13
1. Introduction.....	13
2. Vascular reactivity of epineurial arterioles of the sciatic nerve.....	14
3. Pathogenesis of diabetes and neurovascular tissue.....	15
3.1 Role of reactive oxygen species in diabetes-induced vascular dysfunction.....	15
3.2 Prevention of oxidative stress as treatment for diabetic vascular and neural dysfunction.....	17
4. Conclusions.....	22
I.2 Distal Sensorimotor Neuropathy: Improvements in Diagnosis by Prashanth R. Vas, Sanjeev Sharma & Gerry Rayman.....	29
1. Introduction.....	29
2. Definition and severity assessment of diabetic sensorimotor neuropathy (DSPN).....	30
2.1 Toronto consensus on the determination of diabetic neuropathy.....	20
2.2 Severity assessment.....	31
3. Diagnostic techniques for DSPN.....	33
3.1 Small fiber neuropathy (SFN) - definition and classification.....	34
3.2 Methods for assessment of small fiber neuropathy.....	34
3.3 Methods for assessment of large fiber neuropathy.....	38
4. Validation of normative values.....	41
5. Genetic studies in DSPN.....	41
6. Summary.....	41
I.3 Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015 by Nikolaos Papanas & Dan Ziegler.....	48
1. Introduction.....	48
2. Search strategy.....	48
3. Risk factors of distal symmetric sensorimotor polyneuropathy.....	49
3.1 Duration of diabetes.....	49
3.2 Hyperglycemia.....	49
3.3 Glycemic variability.....	49
3.4 Pre-diabetes.....	50
3.5 Age.....	50
3.6 Height.....	51
3.7 Hypertension.....	51
3.8 Dyslipidemia.....	51
3.9 Smoking.....	51
3.10 Obesity.....	52
3.11 Metabolic syndrome.....	52
3.12 Insulin resistance.....	52
3.13 Alcohol.....	52
3.14 Hypoinsulinemia.....	52
3.15 Oxidative stress.....	52
3.16 Platelet activation.....	53
3.17 Low vitamin D.....	53
3.18 Inflammation.....	53
3.19 Genetic factors.....	53
3.20 Low physical activity.....	54
3.21 Growth factor depletion.....	54
4. Comorbidities of DSPN.....	54
4.1 Depression.....	54
4.2 Cognitive dysfunction.....	54
4.3 Autonomic neuropathy.....	54
4.4 Peripheral arterial disease.....	54
4.5 Medial arterial calcification.....	55
4.6 Cardiovascular disease.....	55

4.7 Nephropathy.....	55
4.8 Retinopathy.....	55
4.9 Obstructive sleep apnea.....	55
4.10 Cardiovascular disease.....	55
5. Discussion.....	55
6. Conclusions.....	56
I.4 Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions by Saad Javed, Uazman Alam & Rayaz A. Malik.....	63
1. Introduction.....	63
2. Diagnosis and assessment.....	64
3. Pathogenetic treatments.....	66
3.1 Glycemic control.....	66
3.2 Pancreas transplantation.....	68
3.3 α -lipoic acid.....	69
3.4 Aldose reductase inhibitors.....	69
3.5 Benfotiamine.....	69
3.6 Angiotensin-converting enzyme (ACE) inhibitors.....	70
3.7 Protein kinase C activation.....	70
3.8 C-peptide.....	70
3.9 Actovegin.....	70
3.10 Other pathogenetic treatments.....	70
4. Symptomatic treatment.....	71
4.1 Tricyclic agents.....	71
4.2 Serotonin norepinephrine reuptake inhibitors (SNRIs).....	72
4.3 Anti-convulsants.....	72
4.4 Opioid analgesia.....	73
4.5 Topical therapies.....	73
5. Non-pharmacological approaches.....	74
6. Combination therapy for DPN.....	74
7. Upcoming strategies for the treatment of painful neuropathy.....	75
8. Diabetic autonomic neuropathy (DAN).....	76
8.1 Cardiac autonomic neuropathy.....	76
8.2 Gastrointestinal autonomic neuropathy.....	77
8.3 Genitourinary autonomic neuropathy.....	77
9. Conclusions.....	77
Chapter II. Diabetic Nephropathy.....	85
II.1 Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease by Giorgina B. Piccoli, Giorgio Grassi, Gianfranca Cabiddu, Maria Nazha, Simona Roggero, Irene Capizzi, Agostino De Pascale, Adriano M. Priola, Cristina Di Vico, Stefania Maxia, Valentina Loi, Anna M. Asumis, Antonello Pani & Andrea Veltri.....	87
1. Introduction.....	87
2. Disease of the “survivors”: a parallel to dialysis.....	88
3. The profile of diabetic nephropathy in type 1 diabetic patients.....	89
4. Characteristics of the renal lesions in diabetic nephropathy.....	90
5. The “renal-retinal syndrome” and indications for kidney biopsy.....	91
6. Diabetic nephropathy in type 2 diabetes: diabetes as a disease, or diabetes as a comorbid condition?.....	94
7. Progressive renal decline and non-albuminuric diabetic nephropathy: a new paradigm in type 1 diabetes.....	94
8. The changing pattern of glomerulosclerosis: a lesion rather than a disease.....	94
9. Incidental association of glomerular diseases and diabetes: just a question of probability?.....	95
10. Impairment of kidney function in diabetic patients: metabolic aspects beyond GFR.....	95
11. Other chronic kidney diseases associated with diabetes: vascular kidney disease, renal infarction, and cholesterol emboli syndrome.....	95
12. Upper urinary tract infection as another acute and chronic kidney disease associated with diabetes.....	97
12.1 Upper urinary tract infections.....	97
12.2 Acute pyelonephritis and upper urinary tract infection.....	97
12.3 Adverse environmental and drug-disease effects and acute or chronic renal impairment.....	98
13. Conclusions.....	99
II.2 Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis by Konstantinos Tziomalos & Vasilios G. Athyros.....	110
1. Introduction.....	110
2. Risk factors for diabetic nephropathy (Table 1).....	111

2.1 Increased urinary albumin excretion.....	111
2.2 Elevated glucose levels.....	111
2.3 Other established risk factors for diabetic nephropathy.....	111
2.4 New risk factors for diabetic nephropathy.....	112
3. Diagnosis of diabetic nephropathy.....	113
4. Novel markers for the early diagnosis of diabetic nephropathy.....	113
6. Conclusions.....	114
II.3 Improvements in the Management of Diabetic Nephropathy by <i>Evangelia Dounousi, Anila Duni, Konstantinos Leivaditis, Vasilios Vaios, Theodoros Eleftheriadis & Vassilios Liakopoulos</i>	119
1. Introduction.....	119
2. Pathophysiological insights as potential therapeutic targets in diabetic nephropathy.....	120
3. Glycemic control.....	121
4. The renin-angiotensin system (RAS).....	123
5. Blood pressure goals in diabetic nephropathy.....	124
6. Aggressive lipid control.....	125
7. Novel targets in therapy.....	125
8. Conclusions and future challenges.....	126
II.4 Targeting Mitochondria- and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy by <i>Runa Lindblom, Gavin Higgins, Melinda Coughlan & Judy B. de Haan</i>	134
1. Introduction.....	134
2. Contribution of ROS/NS production to diabetic nephropathy.....	135
3. Mitochondrial ROS/NS in the pathogenesis of diabetic nephropathy.....	136
4. Consequences of oxidative stress in the diabetic kidney.....	139
4.1 Nuclear DNA damage.....	139
4.2 Mitochondrial DNA damage.....	140
4.3 Compromised DNA repair mechanisms.....	140
5. Modes of cell death during diabetic renal disease.....	140
5.1 Induction of apoptosis.....	141
5.2 Endoplasmic reticulum stress.....	142
5.3 Cellular senescence.....	143
6. Mitochondrial permeability transition as a pathway to renal injury.....	143
7. Targeting mitochondrial ROS in diabetic nephropathy.....	145
8. Concluding remarks and future perspective.....	147
Chapter III. Diabetic Retinopathy.....	157
III.1 Biomarkers in Diabetic Retinopathy by <i>Alicia J. Jenkins, Mugdha V. Joglekar, Anandwardhan A. Hardikar, Anthony C. Keech, David N. O'Neal & Andrzej S. Januszewski</i>	159
1. Introduction.....	159
2. Diabetes mellitus and diabetic retinopathy.....	160
3. Biomarkers.....	162
3.1 Definition.....	162
3.2 Differences between a biomarker, a risk factor, and a determinant.....	162
3.3 Types of biomarkers.....	162
3.4 Why use biomarkers?.....	163
4. Challenges in the development and use of biomarkers.....	164
4.1 Multiple risk factors and diagnostic criteria.....	164
4.2 Slow development of diabetic retinopathy.....	165
4.3 Subclinical retinal damage and metabolic memory.....	165
4.4 Usefulness of biomarkers in independent populations.....	166
4.5 Predictors at population level may not apply to all individuals.....	166
4.6 Microenvironments at tissue, cellular, and molecular level.....	166
4.7 Readily accessible tissues and the site of disease.....	166
4.8 Relevant tissue accessibility and assay availability.....	167
4.9 Dissecting cause and effect.....	167

5. Factors that may affect biomarker assay results.....	167
5.1 Pre-analytical factors.....	167
5.2 Analytical factors.....	167
5.3 Post-analytical factors.....	168
5.4 Funding and biobanking.....	169
6. Characteristics of a reliable biomarker.....	169
7. Biomarkers of interest in diabetic retinopathy.....	169
7.1 Ocular-based biomarkers.....	169
7.2 Glucose-related biomarkers.....	173
7.3 Factors related to advanced glycation end-products (AGEs).....	174
7.4 Lipid- and lipoprotein-related biomarkers.....	176
7.5 Blood pressure.....	177
7.6 Inflammation.....	178
7.7 Thrombosis-related biomarkers.....	179
7.8 Angiogenesis-related biomarkers.....	179
7.9 Oxidative stress markers.....	180
7.10 Nutrition-related biomarkers.....	180
8. Molecular biomarkers.....	181
8.1 GWAS and SNPs.....	181
8.2 Telomeres.....	181
8.3 Epigenetics.....	182
9. Emerging biomarkers.....	183
9.1 'Omics' platforms.....	183
9.2 Tear analysis.....	183
10. Conclusions and future directions.....	184
III.2 New Therapeutic Approaches in Diabetic Retinopathy by <i>Kamyar Vaziri, Stephen G. Schwartz, Nidhi Relhan, Krishna Kishor & Harry W. Flynn Jr.</i>	196
1. Background.....	196
1.1 Epidemiology.....	196
1.2 Risk factors.....	197
1.3 Diabetic retinopathy projections and need for treatment.....	197
2. Current treatment.....	197
2.1 Control of modifiable risk factors.....	197
2.2 Photocoagulation.....	198
2.3 Corticosteroids.....	199
2.4 Anti-VEGF agents.....	200
2.5 Pars plana vitrectomy.....	202
3. Emerging new treatments for diabetic retinopathy and diabetic macular edema.....	202
3.1 Proliferative diabetic retinopathy (PDR) and non-proliferative diabetic retinopathy (NPDR).....	203
3.2 Diabetic macular edema (DME).....	203
4. Novel drug delivery methods.....	205
5. Novel utilizations of diagnosis and testing modalities in diabetic retinopathy.....	205
6. Conclusions.....	205
Chapter IV. Cardiovascular autonomic neuropathy.....	211
IV.1 Simplified Diagnosis of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Using Ewing's Battery by <i>Kalliopi Pafili, Grigorios Trypsianis, Dimitrios Papazoglou, Efstratios Maltezos & Nikolaos Papanas</i>	213
1. Introduction.....	213
2. Patients and methods.....	214
2.1 Patients.....	214
2.2 Statistical analysis.....	215
3. Results.....	215
4. Discussion.....	216
4. Conclusions.....	218